Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma, Hepatocellular
/ etiology
Case-Control Studies
Child
Female
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Hepatitis B, Chronic
/ complications
Histone-Lysine N-Methyltransferase
/ genetics
Humans
Liver Cirrhosis
/ etiology
Liver Neoplasms
/ etiology
Male
Middle Aged
Minisatellite Repeats
Polymorphism, Genetic
Promoter Regions, Genetic
Risk Factors
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 02 2020
18 02 2020
Historique:
received:
05
06
2019
accepted:
03
02
2020
entrez:
20
2
2020
pubmed:
20
2
2020
medline:
20
11
2020
Statut:
epublish
Résumé
SMYD3 (SET and MYND domain-containing protein 3) is involved in histone modification, which initiates oncogenesis by activating transcription of multiple downstream genes. To investigate associations of variable numbers of tandem repeats (VNTR) variants in the SMYD3 gene promoter, SMYD3 serum levels and SMYD3 mRNA expression in hepatitis B virus (HBV) infection and clinical progression of related liver disease. SMYD3 VNTRs were genotyped in 756 HBV patients and 297 healthy controls. SMYD3 serum levels were measured in 293 patients and SMYD3 mRNA expression was quantified in 48 pairs of hepatocellular tumor and adjacent non-tumor liver tissues. Genotype SYMD3 VNTR 3/3 was more frequent among HCC patients than in controls (P
Identifiants
pubmed: 32071406
doi: 10.1038/s41598-020-59667-z
pii: 10.1038/s41598-020-59667-z
pmc: PMC7029004
doi:
Substances chimiques
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
SMYD3 protein, human
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2797Références
WHO. Hepatitis B. (2017).
Nguyen, V. T. Hepatitis B infection in Vietnam: current issues and future challenges. Asia Pac. J. Public. Health 24, 361–373, https://doi.org/10.1177/1010539510385220 (2012).
doi: 10.1177/1010539510385220
pubmed: 21159700
Lee, M. H. et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 58, 546–554, https://doi.org/10.1002/hep.26385 (2013).
doi: 10.1002/hep.26385
pubmed: 23504622
WHO. Hepatitis B in Vietnam. (2018).
GLOBOCAN. The cancer rates in Vietnam. (2018).
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424, https://doi.org/10.3322/caac.21492 (2018).
doi: 10.3322/caac.21492
Ma, L., Chua, M. S., Andrisani, O. & So, S. Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J. Gastroenterol. 20, 333–345, https://doi.org/10.3748/wjg.v20.i2.333 (2014).
doi: 10.3748/wjg.v20.i2.333
pubmed: 24574704
pmcid: 3923010
McCabe, M. T., Mohammad, H. P., Barbash, O. & Kruger, R. G. Targeting Histone Methylation in Cancer. Cancer J. 23, 292–301, https://doi.org/10.1097/PPO.0000000000000283 (2017).
doi: 10.1097/PPO.0000000000000283
pubmed: 28926430
Spellmon, N., Holcomb, J., Trescott, L., Sirinupong, N. & Yang, Z. Structure and function of SET and MYND domain-containing proteins. Int. J. Mol. Sci. 16, 1406–1428, https://doi.org/10.3390/ijms16011406 (2015).
doi: 10.3390/ijms16011406
pubmed: 25580534
pmcid: 4307310
Kunizaki, M. et al. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 67, 10759–10765, https://doi.org/10.1158/0008-5472.CAN-07-1132 (2007).
doi: 10.1158/0008-5472.CAN-07-1132
pubmed: 18006819
Zou, J. N. et al. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Lett. 280, 78–85, https://doi.org/10.1016/j.canlet.2009.02.015 (2009).
doi: 10.1016/j.canlet.2009.02.015
pubmed: 19321255
Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6, 731–740, https://doi.org/10.1038/ncb1151 (2004).
doi: 10.1038/ncb1151
pubmed: 15235609
Luo, X. G. et al. Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells. IUBMB Life 61, 679–684, https://doi.org/10.1002/iub.216 (2009).
doi: 10.1002/iub.216
pubmed: 19472189
Liu, Y. et al. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer. Med. Oncol. 32, 404, https://doi.org/10.1007/s12032-014-0404-y (2015).
doi: 10.1007/s12032-014-0404-y
pubmed: 25471787
Hamamoto, R. et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97, 113–118, https://doi.org/10.1111/j.1349-7006.2006.00146.x (2006).
doi: 10.1111/j.1349-7006.2006.00146.x
pubmed: 16441421
Mazur, P. K. et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nat. 510, 283–287, https://doi.org/10.1038/nature13320 (2014).
doi: 10.1038/nature13320
Yang, L., He, J., Chen, L. & Wang, G. Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells. Med. Oncol. 26, 445–451, https://doi.org/10.1007/s12032-008-9144-1 (2009).
doi: 10.1007/s12032-008-9144-1
pubmed: 19082926
Hayashi, M. et al. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation. Microbiol. Immunol. 60, 17–25, https://doi.org/10.1111/1348-0421.12345 (2016).
doi: 10.1111/1348-0421.12345
pubmed: 26616333
Guo, L., Guo, Y., Xiao, S. & Shi, X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci. 77, 1869–1878, https://doi.org/10.1016/j.lfs.2005.03.019 (2005).
doi: 10.1016/j.lfs.2005.03.019
pubmed: 15927205
Tsuge, M. et al. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5′ flanking region of SMYD3 is a risk factor for human cancers. Nat. Genet. 37, 1104–1107, https://doi.org/10.1038/ng1638 (2005).
doi: 10.1038/ng1638
pubmed: 16155568
Sarris, M. E., Moulos, P., Haroniti, A., Giakountis, A. & Talianidis, I. Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development. Cancer Cell 29, 354–366, https://doi.org/10.1016/j.ccell.2016.01.013 (2016).
doi: 10.1016/j.ccell.2016.01.013
pubmed: 26908355
Liu, T. T. et al. SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer. Med. Sci. Monit. 22, 5131–5140 (2016).
doi: 10.12659/MSM.898095
Wang, H. et al. Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking. Cancer Sci. 99, 787–791, https://doi.org/10.1111/j.1349-7006.2008.00729.x (2008).
doi: 10.1111/j.1349-7006.2008.00729.x
pubmed: 18294291
Li, R. D. et al. The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population. Pathol. Res. Pract. 214, 625–630, https://doi.org/10.1016/j.prp.2018.04.005 (2018).
doi: 10.1016/j.prp.2018.04.005
pubmed: 29691085
Hoan, N. X. et al. SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. Oncotarget 8, 17127–17139, https://doi.org/10.18632/oncotarget.15083 (2017).
doi: 10.18632/oncotarget.15083
pubmed: 28179578
pmcid: 5370028
Cholongitas, E. et al. Systematic review: The model for end-stage liver disease–should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment. Pharmacol. Ther. 22, 1079–1089, https://doi.org/10.1111/j.1365-2036.2005.02691.x (2005).
doi: 10.1111/j.1365-2036.2005.02691.x
pubmed: 16305721
Diaz-Gonzalez, A., Reig, M. & Bruix, J. Treatment of Hepatocellular Carcinoma. Dig. Dis. 34, 597–602, https://doi.org/10.1159/000445275 (2016).
doi: 10.1159/000445275
pubmed: 27332893
Cillo, U. et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J. Hepatol. 44, 723–731, https://doi.org/10.1016/j.jhep.2005.12.015 (2006).
doi: 10.1016/j.jhep.2005.12.015
pubmed: 16488051
Wang, X. Q., Miao, X., Cai, Q., Garcia-Barcelo, M. M. & Fan, S. T. SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population. Exp. Oncol. 29, 71–73 (2007).
pubmed: 17431393
Harbour, J. W. & Dean, D. C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes. Dev. 14, 2393–2409 (2000).
doi: 10.1101/gad.813200
Stevaux, O. & Dyson, N. J. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14, 684–691 (2002).
doi: 10.1016/S0955-0674(02)00388-5
Chen, L. B., Xu, J. Y., Yang, Z. & Wang, G. B. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World J. Gastroenterol. 13, 5718–5724 (2007).
doi: 10.3748/wjg.v13.i43.5718
Wang, Y. et al. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2. Oncogene 38, 4948–4961, https://doi.org/10.1038/s41388-019-0766-x (2019).
doi: 10.1038/s41388-019-0766-x
pubmed: 30842588
Fei, X., Ma, Y., Liu, X. & Meng, Z. Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma. Tohoku J. Exp. Med. 243, 219–226, https://doi.org/10.1620/tjem.243.219 (2017).
doi: 10.1620/tjem.243.219
pubmed: 29187705
Chen, Z. et al. A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3beta-Signaling Pathways. Mol. Ther. Nucleic Acids 16, 707–720, https://doi.org/10.1016/j.omtn.2019.04.021 (2019).
doi: 10.1016/j.omtn.2019.04.021
pubmed: 31128422
pmcid: 6535504
Zhou, Z. et al. ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 38, 18, https://doi.org/10.1186/s13046-018-1011-0 (2019).
doi: 10.1186/s13046-018-1011-0
pubmed: 30646949
pmcid: 6332640